Company Introduction

  • Mabpharm Limited (2181.HK) is a publicly listed company on the Hong Kong Stock Exchange, specializing in the research, development, and production of new drugs and biosimilars for the treatment of cancer and autoimmune diseases. We are dedicated to bringing high-quality, affordable, and innovative biopharmaceuticals to the market through an efficient research and development (R&D) system, low-cost drug production capabilities, and our extensive R&D experience to develop a diverse range of therapeutic products.

    Over the years, Mabpharm has extensively explored the field of biomedical R&D and innovation, mastering core technologies for the large-scale production of novel antibody drugs and establishing a comprehensive platform for R&D innovation, and industrialization. Currently, the company has successfully obtained approval for the marketing of three antibody drugs.

    We have a strong foundation in equipment, technology, and quality in the field of antibody drug production. Leveraging our domestic advantages in antibody drug R&D and industrialization capabilities, we are actively expanding and implementing our Contract Development and Manufacturing Organization (CDMO) business without compromising our own product development. The company has a well-established organizational structure, covering departments including R&D, production, quality control and clinical trials.

Production Base

  • Large scale antibody GMP production base

    Taizhou Mabtech Pharmaceutical Co., Ltd.

    Taizhou Mabtech Pharmaceutical Co., Ltd. was established in February 2015 as a wholly-owned subsidiary of Mabpharm Limited. It is located at Building G79, west of Koutai Road and east of Lujia Road in the China Medical City, Taizhou, with a registered capital of USD 210 million. The company is primarily engaged in the research, development, and industrialization of antibody drugs.

    The company currently operates ‌two production bases‌, with the ‌G79 Production Base‌ covering an area of 30,000 square meters‌ and is equipped with four 3x1,500 liter antibody bioreactor systems along with related purification lines, one injection filling line (capable of producing four million vials annually), and one prefilled syringe injection production line (capable of producing one million units annually). Our ongoing Xiangtai Road Production base project has completed the first phase: key process equipment for drug substance has finished trial production and the filling line has acquired the official approval and been put into use. Upon full completion, the total scale of the cell reactors is expected to reach 40,000 liters‌.

  • 20 Years of Experience in Antibody Research and Production Manufacturing

    Through years of research and development, we have accumulated extensive experience and knowledge, building a strong R&D capability. With our deep roots in the field of antibody drug R&D and manufacturing, we have developed multiple antibody drugs, secured numerous patents, and earned several awards, establishing ourselves as a leader in the industry.

  • A Rich Reserve of Drug Pipelines

    We are continuously enriching our product pipeline and accelerating the advancement of new drug R&D and clinical trials. Our goal is to achieve further breakthroughs in the field of innovative drugs, thereby advancing new drug development and providing patients with more and better treatment options.

  • Comprehensive Quality System Guarantee

    ‌By establishing and improving the quality management system, Mabpharm Limited can systematically identify, control, and prevent potential quality risks, ensuring the safety and efficacy of its products while building a strong market reputation.